Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith joined Proactive's Stephen Gunnioin from LSX USA Congress in Boston, where the company is connecting with potential partners and healthcare investors.
Sturgess-Smith shared insights on the drug development company's £2.15 million fundraising effort, which received significant support from chairman Charles Morgan. "He’s put his money where his mouth is once again," Sturgess-Smith commented, reflecting on Morgan's cornerstone contribution.
The raised funds will primarily support the manufacture of MRX1 for two Phase 2 studies. Additionally, Ananda will conduct a Phase 1 pharmacokinetic study to better understand dosage parameters. Sturgess-Smith highlighted that the company will focus on moving MRX1 through pretrial regulatory pathways over the next six months, with plans to conduct the pharmacokinetic study in Australia due to its world-class Phase 1 study ecosystem.